Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-23
2007-01-23
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
10273386
ABSTRACT:
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages. In certain embodiments, the peptides range in length from about 10 up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent.
REFERENCES:
patent: 3767040 (1973-10-01), Tushaus
patent: 4155913 (1979-05-01), Hellerbach et al.
patent: 4643988 (1987-02-01), Segrest et al.
patent: 4684520 (1987-08-01), Bertelli
patent: 5298490 (1994-03-01), Heavner et al.
patent: 5344822 (1994-09-01), Levine et al.
patent: 5595973 (1997-01-01), Bogden
patent: 5721138 (1998-02-01), Lawn
patent: 5733549 (1998-03-01), Yamada et al.
patent: 5733879 (1998-03-01), Rosseneu et al.
patent: 5814467 (1998-09-01), Curtiss et al.
patent: 5854238 (1998-12-01), Kempen
patent: 6004925 (1999-12-01), Dasseux et al.
patent: 6037323 (2000-03-01), Dasseux et al.
patent: 6046166 (2000-04-01), Dasseux et al.
patent: 6086918 (2000-07-01), Stern et al.
patent: 6265377 (2001-07-01), Dasseux et al.
patent: 6287590 (2001-09-01), Dasseux et al.
patent: 6329341 (2001-12-01), Dasseux et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 6455088 (2002-09-01), Dasseux et al.
patent: 6518412 (2003-02-01), Dasseux et al.
patent: 6573239 (2003-06-01), Dasseux et al.
patent: 6602854 (2003-08-01), Dasseux et al.
patent: 6630450 (2003-10-01), Dasseux et al.
patent: 6664230 (2003-12-01), Fogelman et al.
patent: 6696545 (2004-02-01), Buelow et al.
patent: 6716816 (2004-04-01), Dasseux et al.
patent: 6734169 (2004-05-01), Dasseux et al.
patent: 6753313 (2004-06-01), Dasseux et al.
patent: 6933279 (2005-08-01), Fogelman et al.
patent: 2001/0005714 (2001-06-01), Boffelli et al.
patent: 2002/0042441 (2002-04-01), Acton et al.
patent: 2003/0027769 (2003-02-01), Scialdone et al.
patent: 2003/0040505 (2003-02-01), Fogelman et al.
patent: 2003/0045460 (2003-03-01), Fogelman et al.
patent: 2003/0125260 (2003-07-01), Haviv et al.
patent: 185761 (2004-04-01), None
patent: WO 96/41815 (1996-12-01), None
patent: WO 97/36927 (1997-10-01), None
patent: WO 97/36927 (1997-10-01), None
patent: WO 99/16408 (1999-04-01), None
patent: WO 99/47566 (1999-09-01), None
Tan et al. (1997) “A Novel, Highly Efficient Peptide-HLA Class TH:ca Binding Assay Using Unfolded Heavy Change Molecules: Identification of HIV-1 Derived Peptides that Bind to HLA-A* 0201 and HLA-A* 0301” Journal of Immunological Methods vol. 205, pp. 201-209.
Aravinda, S., Shamala, N., Das, C. , Sriranjini, A. , Karle, I. And Balaram, P. Aromatic—Aromatic Interactions in Crystal Structures of Helical Peptide Scaffolds Containing Projecting Phenylalinine Residues, J.Am Chem Soc. 2003; 125:5308-5315.
Ashby D, Gamble J, Vadas M, Fidge N, Siggins S, Rye K, Barter PJ. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression.Atherosclerosis. 2001;154:113-121.
Ashby DT, Rye K-A, Clay MA., Vadas MA, Gamble J, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells.Arteriosclerosis, Thrombosis and Vascular Biology, 1998,18:1450-1455.
Baker PW, Rye K-A, Gamble JR, Vadas MA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical cell endothelial cells.Journal of Lipid Research, 1999, 40:345-353.
Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression.J Lipid Res2000;41:1261-1267.
Barter PJ, Baker PW, Rye K-A.. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells.Current Opinion in Lipidology, 2002, 13:285-288.
Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease.Atherosclerosis, 1996, 121:1-12.
Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease.Circulation2001;104:1336-1342.
Bourdillon MC, Poston RN, Covacho C, Chignier E, Bricca G, McGregor JL. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet.Arterioscler Thromb Vasc Biol2000;20:2630-2635.
Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors.Proc Natl Acad SciU S A. 1992;89:10316-10320.
Burger D, Dayer J-M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?Autoimmunity Reviews2002;1:111-117.
Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, Taramellin D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins.Biochem Biophys Res Commun. 1997;238:61-65.
Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G. Elevated cellular adhesion molecules in subjects with low HDL-cholesterol.Arterioscler Thromb Vasc Biol2002;22:656-661.
Carlos TM, Schartz BR, Kovach NL, Yee E, Rosa M, Osborn L, Chi-Rosso G, Newman B, Lobb R, Rosso M, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells.Blood1990;76:965-970.
Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species oxidation of LDL by myeloperoxidase and reactive nitrogen species.Arterioscler Thromb Vasc Biol. 2000;20:1716-1723.
Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Farmingham study.JAMA1986;256:2835-2838, (Abstract only).
Chiesa G, Monteggia E, Marchesi M, Lorenzon P, Laucello M, Lorusso V, Di Mario C, Karvouni E, Newton RS, Bisgaier CL, Franceschini G, Sirtori CR. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks.Circ Res. 2002;90:974-980.
Christison J, Karjalainen A, Brauman J, Bygrave F, Stocker R. Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ.Biochem J. 1996;314:739-742.
Clay MA, Pyle DH, Rye K-A, Vadas MA, Gamble JR, Barter PJ. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins.Atherosclerosis, 2001,157:23-29.
Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-1induced expression of E-selectin in an in vivo model of acute inflammation.Circulation2001;103:108-112.
Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules.Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
Cockerill GW, Saklatvala J, Ridley SH, Yarwood H, Miller NE, Oral B, Nithyanathan S, TaylorG, Haskard DO. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2.Arterioscler Thromb Vasc Biol. 1999;19:910-917.
Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis.Journal of Clinical Investigation2001;107:1255-1262.
Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and athergenesis in apolipoprotein E-deficient mice.Circulation. 2001;103:2277-2282.
Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, Smith JD. Adhesion of monocytes to arteri
Anantharamaiah Gattadahalli M
Fogelman Alan M
Navab Mohamad
Beyer weaver & Thomas
Hunter Tom
Russel Jeffrey Edwin
The Regents of the University of California
The University of Alabama Research Foundation
LandOfFree
Orally administered peptides synergize statin activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally administered peptides synergize statin activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administered peptides synergize statin activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805644